- Credit Suisse upgrades PharMerica (PMC) to Outperform and raises its price target from $19 to $30.
- Analyst Glen Santangelo cites the company's accelerating growth profile as the main reason for his bullish outlook.
- Consensus estimates for 2014 and 2015 are $1.47/share on revenues of $1.68B and $1.75/share on revenues of $1.72B, respectively.
- 282 mutual funds have positions.
at Zacks.com (Oct 27, 2014)